Status:
COMPLETED
Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRI
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Hepatocellular Carcinoma (HCC)
Eligibility:
All Genders
20-70 years
Phase:
NA
Brief Summary
Hepatocellular carcinoma (HCC) is unique regarding diagnosis because the clinical diagnosis without pathology proof is accepted. The dynamic image, including contrast-enhanced computed tomography (CEC...
Detailed Description
The liver cancers including hepatocellular carcinoma (HCC) resulted in more than 7,000 mortalities in Taiwan every year. HCC is unique regarding diagnosis because the clinical diagnosis without pathol...
Eligibility Criteria
Inclusion
- Age 20-70
- All patients presented with newly diagnosed liver lesion(s) with initial impression of malignancy.
- Lesions no larger than 3cm in diameter.
- Signed and dated informed consent
Exclusion
- The lesion with previously documented histology
- The lesion previously treated with Percutaneous Ethanol Injection, Radiofrequency Ablation, or Transarterial Chemoembolization
- The lesion will not have histological confirmation after differential diagnosis
- The subject had known hypersensitivity to any component of Sonazoid, including a history of allergies to eggs or egg products (i.e., manifested by full body rash, respiratory difficulty, oral or laryngeal swelling, hypotension or shock).
- The subject was considered to be unsuitable to participate in the study by the investigator.
- The subject was known to have a right-to-left shunt, severe pulmonary hypertension (pulmonary artery pressure \>90 mmHg) or uncontrolled systemic hypertension.
- The subject had a recent acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: evolving or ongoing myocardial infarction, typical angina at rest within the last 7 days, significant worsening of cardiac symptoms within the last 7 days, recent coronary artery intervention or other factors suggesting clinical instability (e.g., recent deterioration of electrocardiogram, laboratory or clinical findings), acute cardiac failure, Class III/IV cardiac failure, or severe rhythm disorders.
- The subject had adult respiratory distress syndrome, severe emphysema, pulmonary vasculitis, or a history of pulmonary emboli.
- The subject had known thrombosis within the liver, or portal, or mesenteric veins.
- The patient with iodine/Gd allergy, lower epidermal growth factor receptor level(\<50), liver/renal dysfunction, and other condition that unsuitable to receive contrast
- Pregnant and breastfeeding women
Key Trial Info
Start Date :
July 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 11 2019
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT03267290
Start Date
July 1 2017
End Date
January 11 2019
Last Update
July 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan